The IGTP-GTP biobanc has won an award for the best oral presentation of a poster, for the team's work on analysing the work of the biobanc over the past 5 years and evaluating the balance between samples stored and requests for samples made. The team demonstrated that the biobanc is dynamic, receiving a steady increase of requests for samples and is able to respond to changing needs from researchers.
At the IGTP TODAY
A team at Germans Trias treat a patient with a new bio-implant to repair heart tissue after a heart attack
The pioneering surgery that took place last May at the Germans Trias Hospital. The bio-implant, based on umbilical cord stem cells, has been developed by the Cardiovascular Disease Research Group (ICREC) at Germans Trias, led by Antoni Bayés-Genís in a research line, which they have been pursuing for 10 years. The new therapy has been developed with the collaboration of the Blood and Tissue Bank (BST) and the Institute of Bioengineering of Catalonia (IBEC); this is the first step of the application in clinical practice and the group will continue to monitor safety and the capacity of cardiac tissue to recover
Two groups at the IGTP have taken part in the workshop "Complex Systems" organized by the Èpica Foundation. The experience is a first for the IGTP and has meant that art and science have worked together to produce results for both of them. Èpica is a space for interdisciplinary learning and training for the performing arts run by the Fura dels Baus. The results of the workshop are based on research projects from the IGTP and will be shown this Friday and Saturday 29 and 30 November at the Èpica headquarters in Badalona.
The Neuromuscular and Neuropediatric Group at the IGTP, led by Gisela Nogales-Gadea have identified a subset of patients with an atypical type of myotonic dystrophy type 1 (MD1), which develops later and with more severe symptoms than usual. This has important implications for diagnosis of these patients, who can be misdiagnosed or not given the correct prognosis. It is also vital for managing the disease correctly in patients and their families. The study has been published in Human Mutation.
Last Friday the first update meeting at national level to take a global view of the healthcare situation and present the latest research data for Neurofibromatosis type 2 (NF2) took place at the IGTP. This pioneering event was organized by the members of the National Reference Centre in genetic neuro-cutaneous syndromes (Facomatosis), (CSUR) on the Can Ruti Campus and also included patients and families affected by the disease.
To celebrate World Diabetes Day we will literally be talking about the illness at the IGTP; several members of the Immunology of Diabetes Group, which is led by Marta Vives-Pi and concentrates on research into diabetes type 1, will be taking part in talks and discussions in scientific and public forums during the next few days.
Researchers from the Germans Trias i Pujol Hospital and Institute have developed and successfully validated a new one-step screening method to diagnose active hepatitis C virus (HCV) infection in people who inject drugs. The new method will permit better planning of future more effective actions to improve diagnostics and treatments for this vulnerable group. The study also estimated the prevalence of HCV infection in this community and showed that many people tested do not know that they are infected.
Researchers reveal how beta cells in the pancreas respond to an inflammatory environment and how this response is implicated in the risk of developing Type 1 diabetes
The results point to a much more active role for pancreatic beta cells in type 1 diabetes than previously appreciated and suggests a mechanism that may play a key role in other auto-immune diseases.
Yesterday evening the ceremony to present awards to the 43 projects that will receive funding for cancer research from the 2018 edition of the La Marató de TV3 and Catalunya Radio was held at the Academy of Medical Sciences. Three of the projects will be carried out under the leadership of Germans Trias professionals.
In 2017 the team designed and tested a gene panel, in collaboration with the ICO, to standardize and simplify genetic testing for hereditary cancer. In the current work the group has validated and extended the use of this panel in the routine genetic testing for different RASopathies. These are other genetic diseases caused by mutations in genes of the Ras/MAPK pathway for which patients exhibit an overlapping clinical presentation with NF1, especially in children.